As part of our ongoing aim to bring you reports of significant or innovative developments, we have added a review of a series of studies examining real-world usage of Baricitinib in patients with rheumatoid arthritis.
Independent commentary is provided by Dr Mona Marabani, a rheumatologist in practice in western Sydney who heads the department of medicine at Canterbury Hospital.
Please login below to download this issue (PDF)